Related Experiment Video
Updated: Aug 9, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[The diagnostic significance of blast immunophenotype assay in patients with acute leukemia]
B Piatoska-Jakubas1, A Pituch-Noworolska, A B Skotnicki
1Kliniki Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego.
Insights
Immunophenotyping accurately classified acute leukemia subtypes in 96.7% of adult patients. Atypical blast phenotypes were observed in 31%, highlighting the need for precise diagnostic methods in leukemia research.
Area of Science:
- Hematology
- Oncology
- Immunology
Context:
- Acute leukemias represent a heterogeneous group of hematologic malignancies.
- Accurate subtyping is crucial for effective treatment strategies and prognosis.
- Immunophenotyping is a key diagnostic tool in hematologic pathology.
Purpose:
- To analyze the immunophenotypes of adult patients with newly diagnosed acute leukemias.
- To determine the proportion of different acute leukemia subtypes.
- To identify atypical blast phenotypes and their immunophenotypic characteristics.
Summary:
- Immunophenotyping was performed on 120 adult patients with newly diagnosed acute leukemias.
- It successfully classified 96.7% of cases into subtypes: AML (62.5%), ALL (32.5%), acute biphenotypic leukemia (1.7%), and acute undifferentiated leukemia (3.3%).
- Atypical blast phenotypes, including marker co-expressions, were identified in 31% of cases, sometimes differing from initial FAB criteria diagnoses.
Impact:
- Immunophenotyping provides a high diagnostic yield for acute leukemia classification.
- Identification of atypical phenotypes refines our understanding of leukemia heterogeneity.
- This data supports the critical role of immunophenotyping in accurate leukemia diagnosis and potentially guides therapeutic decisions.
Abstract:
A detailed analysis of immunophenotypes of 120 adult newly diagnosed patients with acute leukaemias was performed. Using the immunopheno-typing, it was possible to defined 96,7% of leukemia cases. The proportion of leukemia subtypes was: AML in 62,5%, ALL in 32,5%, acute biphenotypic leukaemia 1,7% and acute undifferentiated leukaemia (AUL) in 3,3%. The diagnosis initially made according FAB criterias in 12,5% cases after the immunophenotyping was verified. Above analyses showed the existence of the atypical blasts phenotypes in 31%: co-expression of CD 19, CD2 and CD7 markers in AML, co-expression of CD 33 marker in ALL, co-expression of CD 19 marker in T cell ALL and biphenotypic (mixed-lineage) leukaemia.
